AUTO 5
Alternative Names: Anti-TRBC2 CAR-T Cells - Autolus; AUTO-5Latest Information Update: 28 Apr 2024
At a glance
- Originator University College London
- Developer Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported T-cell lymphoma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in T-cell-lymphoma in United Kingdom (Parenteral, Infusion)
- 05 Aug 2021 Autolus plans a phase I trial in Peripheral T-cell lymphoma in the first half of 2022
- 22 Jun 2020 Pharmacodynamics data from a preclinical trial in T-cell lymphoma released by Autolus Therapeutics